Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00370565 · ClinicalTrials.gov registry record · Phase 3
Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 345
- Enrollment target
NCT00370565 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 345 participants.
The verdict
NCT00370565, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 345 participants
- Enrollment target
Study Summary
To assess the impact on glucose control by inhaled insulin alone or added to two oral anti-diabetic agents in patients with type 2 diabetes who are not well controlled on 2 oral anti-diabetic agents.
Interventions
- DRUG Inhaled Human Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 1999-06 |
| Est. Completion | 2000-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00370565
The ClinicalTrials.gov registry entry for NCT00370565 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled Human Insulin is the first listed.
NCT00370565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00370565 about?
NCT00370565 is a clinical study titled "Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.". To assess the impact on glucose control by inhaled insulin alone or added to two oral anti-diabetic agents in patients with type 2 diabetes who are not well controlled on 2 oral anti-diabetic agents.
What is the current status of trial NCT00370565?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 345 participants. The study started on 1999-06. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00370565?
The interventions under investigation include: Inhaled Human Insulin (DRUG).
Who is sponsoring clinical trial NCT00370565?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.